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Advanced heart failure (HF) has been defined as 
persistent symptoms that limit daily life despite optical 
medical therapy, corresponding to New York Heart 
Association (NYHA) class III/IV symptoms or to the 
newer classification of stage D HF (ACC/AHA staging 
classification). It affects 10% of the HF population and is 
associated with a poor quality of life, recurrent 
hospitalizations and a mortality approaching 50% at 1 
year and 80% at 5 years.1,2 Despite the widespread use of 
angiotensin converting enzyme (ACE) inhibitors, beta 
adrenergic blocking agents and spironolactone which 
improve the prognosis in mild to moderate stages, HF 
remains a progressive disease leading to decompensation 
and demand of both inotropic agents (class III 
recommendation according to ACC/AHA guidelines, 
considered solely for palliation in patients with end-stage 
disease) and diuretics to treat hypotension, impaired renal 
function and pulmonary congestion.3  
Heart transplantation (HT) is associated with nearly 
90% 1-year survival, 60% 10-year survival and 95% 
freedom from symptoms and activity limitations in 
survivors throughout the follow-up period.1 Nevertheless, 
the lack of available donors and the large number of 
patients, who do not meet the criteria for transplantation, 
have spurred interest in cardiac resynchronization therapy 
(CRT) and mechanical circulatory support (MCS), 
providing alternatives for patients waiting for HT (bridge 
to transplantation, BTT), patients who are ineligible for 
HT (destination therapy, DT) or patients who are 
anticipated to recover after left ventricular unloading 
(bridge to recovery, BTR).     
 
 Cardiac Resynchronization Therapy (CRT) in 
NYHA functional class III/IV 
 
The progression of heart failure results in dilated 
ventricles and impaired conduction between different 
segments of ventricular wall. QRS duration over 120 ms 
is present in 25-40% of patients with advanced HF, with 
left bundle branch block (LBBB) being the most common 
conduction abnormality of both ischemic and non-
ischemic cardiomyopathy. The transvenous insertion of 
both ventricular pacing leads has been proved beneficial 
on the basis of clinical improvement for over half of 
patients with inter-ventricular dyssynchrony undergoing 
CRT.4 Although a wide QRS does not always indicate 
marked dyssynchrony, it is currently the most convenient 
descriptor for considering biventricular pacing to confer 
symptomatic benefit mainly in patients with median QRS 
duration 150-170 ms. Echocardiographic parameters have 
not been adopted, although real-time 3D echo appears 
quite promising in quantifying mechanical dyssynchrony 
by assessing novel parameters, such as the systolic 
dyssynchrony index (SDI).5,6   
CRT has been recommended as a class IA indication 
by both major HF and pacing guidelines for advanced HF 
patients (NYHA III/IV) with QRS ≥ 120 ms, ejection 
fraction (EF) ≤ 35% and sinus rhythm, refractory to 
optimal medical therapy.7 A large number of randomized 
multi-center trials have evaluated CRT-pacing (CRT-P) 
and CRT-defibrillator (ICD) devices (CRT-D) on 
symptoms, exercise tolerance, morbidity and mortality in 
patients with refractory HF. In the COMPANION trial, 
CRT-P decreased the risk of death from or hospitalization 
for HF (primary endpoint) by 34% and the risk of death 
from any cause (secondary endpoint) by 24%, while 
CRT-D was associated with decreased risk of primary 
and secondary endpoints by 40% and 36% respectively.8 
The CARE-HF study showed a reduction in the risk of 
death due to advanced HF (hazard ratio 0.55, P=0.003) 
and sudden death (hazard ratio 0.54, P=0.005) in patients 
with CRT-P who were followed up for a mean period of 
37.4 months9 and also demonstrated improved quality of 
life by 13% at 18 months and by 23% at study-end for 
patients assigned to CRT.10  
According to the results from the MUSTIC study, 
patients with NYHA III and intraventricular conduction 
delay who were followed up at 9 and 12 months after 
CRT-P implantation displayed major clinical and 
echocardiographic improvements, e.g. the 6-minute walk 
distance increased by 20% (patients in sinus rhythm, SR) 
and 17% (patients in atrial fibrillation, AF) / peak VO2 
increased by 11% (SR) and 9% (AF) / quality of life 
improved by 36% (SR) and 32% (AF) / NYHA class 
improved by 25% (SR) and 27% (AF) / EF improved by 
5% (SR) and 4% (AF), mitral regurgitation decreased by 
45% (SR) and 50% (AF).11 Similarly, CRT reduced the 
interventricular mechanical delay, the end-systolic 
volume index, the area of the mitral regurgitation and 
increased the mean EF by 3.7% at 3 months to 6.9% at 18 
months in a sub-analysis of the CARE-HF.12 Effects were 
significantly greater in patients with non-ischemic than in 
ischemic heart disease while prolonged PR interval and 
right bundle branch block were predictors of non-
favorable outcome.13 Less than two thirds of patients 
enrolled in the MIRACLE or MIRACLE-ICD trials 
responded to CRT, with just more than half responding 
within the first month of CRT-P or CRT-D implantation 
(patients with improvement ≥ 1 NYHA class from 
baseline to 6 month follow-up were considered 
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responders and those with no change or worse NYHA 
class were classified as non-responders).14  
A prolonged QRS is widely regarded as a prerequisite 
for CRT but approximately 30-40% of all CRT patients 
are regarded as non-responders; it has been suggested that 
almost 30-40% of HF patients with wide QRS do not 
exhibit ventricular dyssynchrony (non-responders) and 
27% of HF patients with narrow QRS show mechanical 
dyssynchrony and response to CRT.15  In a sub-analysis 
of the PROSPECT trial, patients with narrow QRS 
complex and mechanical dyssynchrony assessed by 
echocardiography, demonstrated benefit by CRT, yet in 
the RethinQ trial patients with similar inclusion criteria 
did not show improved peak oxygen consumption after 
CRT.16,17 Larger studies are needed to clearly define 
criteria for identifying patients likely to benefit from such 
a complex invasive and costly treatment.  
Female sex and advanced age should not be contra-
indications for CRT when appropriate indications exist, 
while patients with right bundle branch block or right 
ventricular dysfunction would probably have a lower 
response to CRT.18 In patients with AF, atrioventricular 
node (AVN) ablation and implantation of CRT provides 
100% biventricular pacing and great improvement in 
NYHA class and survival benefit19 and as a result, it is 
included in the latest guidelines for patients with AF who 
meet criteria for CRT (EF<35%, NYHA III/IV and 
refractory to drug therapy) as a class IIa recommendation.  
 
Mechanical Circulatory Support 
In recent years, technological advancements have 
emerged to help assist the failing heart, alter 
hemodynamics and improve cardiac output. Initial reports 
of mechanical support of the heart date back to the 1960s 
with the development of the intra-aortic balloon pump 
(IABP), and later in 1971 Dr. Michael DeBakey reported 
the first clinical use of a left ventricular assist device 
(LVAD).20  Different devices have been developed since 
then, classified into percutaneous and surgical therapies; 
the former are indicated for short-term use in acutely 
decompensated HF or perioperatively and include the 
ΙΑBP, and continuous aortic flow augmentation (CAFA) 
and catheter-based pumps; the latter are intended for 
long-term treatment of chronic HF and comprise 
ventricular assist devices (VADs) and total artificial 
hearts (TAHs)].21   
 
1. Percutaneous therapies 
The IABP has been in use since the early 1960s, with 
a balloon catheter being inserted through the femoral 
artery and externally controlled, inflated during diastole 
and deflated during systole. It is associated with a 2.8% 
rate of significant complications and a 0.05% rate of in-
hospital mortality which probably reflects the critical 
condition of patients who are selected for IABP therapy. 
The CAFA pump was first tested in the Cancion System 
which circulates blood from catheterized bilateral femoral 
arteries to an extracorporeal pump and then into the 
descending aorta. It was associated with improvement in 
cardiac index but major bleeding in the MOMENTUM 
trial prevented its commercial use.22 A new CAFA 
device, the Exeleras system (fully implantable, intended 
for long-term treatment of HF) is now under development 
and will be the subject of future studies.  
Among different percutaneous catheter-based pumps 
that have been designed to provide short-term 
hemodynamic support in patients with cardiogenic shock, 
the Impella 2.5 is a minimally invasive catheter-based 
cardiac assist device, inserted into the left ventricle via 
the femoral artery with a micro-axial pump continuously 
pumping blood from the left ventricle into the ascending 
aorta at a maximum rate of 2.5 L/min. The TandemHeart 
Percutaneous Transseptal Ventricular Assist (PTVA) 
system is another catheter-based pump which is inserted 
into the left atrium via transseptal puncture with an 
extracorporeal pump (maximum flow rate 5.0 L/min) and 
an outflow catheter positioned into the descending aorta. 
Both the Impella and the TandemHeart PTVA systems 
provide hemodynamic support (improvement in cardiac 
index, increase in mean blood pressure, reduction in 
pulmonary capillary wedge pressure), although no 
difference was found in 30-day mortality between either 
of these systems and IABP. It also seems that outcome is 
better in their prophylactic use for high risk percutaneous 
coronary intervention, while severe adverse effects 
inlcude bleeding and limb ischemia.21,23,24  
 
2. Surgical therapies 
The limitations of medical therapy and the woeful 
shortage of organs for transplantation led to the 
development of ventricular assist devices, mechanical 
pumps that are surgically implanted to support the failing 
left ventricle (LVAD), or right ventricle (RVAD) or both 
(BiVAD). Apart from providing hemodynamic support, 
these devices result in reverse remodeling of the failing 
ventricle by reversing different genetic, cellular and 
neurohormonal pathways taking place in HF.21  
There are three generations of these devices which 
became a cornerstone for the treatment of patients with 
refractory HF, while constant adjustments take place to 
increase their efficiency.25,26 First-generation LVADs are 
large extracorporeal devices for temporary use, the 
Thoratec HeartMate XVE (later called HeartMate I) and 
the Novacor LVAS. The REMATCH study demonstrated 
increased 1- / 2-year survival and improved quality of life 
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for patients who received the HeartMate XVE with deaths 
being attributed to device failure and sepsis.27 A non-
randomized trial with the Novacor LVAS also 
demonstrated improved survival but 62% of patients 
receiving MCS suffered from a stroke or transient 
ischemic stroke.28 Second-generation LVADs (HeartMate 
II, Jarvik 2000 and HeartAssist 5) are continuous-flow 
devices that work with an axial flow mechanism, have 
smaller size, need a more limited surgery, are less likely 
to be infected but need systemic anticoagulation. 
Although second-generation LVADs continue to 
improve, trials evaluating third-generation LVADs are 
taking place including HeartWare HVAD, HeartMate III 
and Synergy, usually using a magnetically levitated 
impeller for moving blood.26  
It is estimated that 80-90% of LVADs are implanted 
in transplant candidates (BTT), although they are also 
used in patients who are deemed too sick to survive and 
have contraindications for transplant (DT) or even as 
‘bridge to decision’ apart from BTR for those who 
require reevaluation and adequate support for 
improvement of end-organ perfusion. Patients with the 
following parameters have a strong indication for the 
implantation of a LVAD: NYHA IV for 60-90 days, 
optimal medical therapy and CRT-P/CRT-D if indicated, 
chronic inotrope dependence, LVEF <25%, PCWP ≥ 20 
mmHg, SBP≤ 80-90 mmHg or cardiac index ≤2 L/min/m2 
or declining renal or right ventricular (RV) function.1 
Patients with severe renal, pulmonary, hepatic 
dysfunction or patients with active infection or 
cardiogenic shock should not be considered as candidates.  
LVADs are associated with 5-10% peri-operative 
mortality and considerable morbidity due to multi-organ 
failure, embolic events, bleeding, infection, sepsis or 
acute RV failure. Certain complications may present over 
the long-term, such as embolic or hemorrhagic stroke, 
progression or de novo development of RV failure, 
human leucocyte antigen sensitization, renal 
insufficiency, device failure or infection requiring 
transplantation, explantation or replacement.1 Risk for 
developing ventricular arrhythmias has also been reported 
and ICD therapy seems safe and effective in LVAD 
patients, associated with extended survival: (i) more than 
one-third of LVAD recipients experience appropriate ICD 
therapy in the first year, (ii) patients with a secondary 
prophylactic ICD indication have a two-fold increased 
risk for appropriate shocks compared with patients with a 
primary prophylactic ICD indication.29,30 
The Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS, www.intermacs.org) 
is a comprehensive VAD registry in the USA with 
approximately 4800 VADs being enrolled until June of 
2011.31 Data collected in this registry made clear that 
preoperative hemodynamic status largely influences the 
prognosis after VAD implantation, leading to detection of 
‘profiles’ and ‘modifiers’ in order to select patients and 
study outcomes in LVAD patients. The 1-year survival 
for LVADs continuously improved from 50% in the 
REMATCH trial to 74% at the second annual 
INTERMACS report and is close to 85% according to 
data presented at the International Society of Heart and 
Lung Transplantation annual meeting in 2010.26  
The FDA has currently approved 2 different TAHs 
in the USA, the CardioWest Temporary Total Artificial 
Heart (as BTT) and the AbioCor Replacement Heart (as 
DT in patients with biventricular HF with no other 
medical or surgical treatment options). Yet, serious 
complications of these devices like bleeding, infection, 
stroke and difficulties regarding battery recharge still 
hold up their use.21 A novel device of cardiac contractility 
modulation (CCM) was tested in FIX-HF-5, a multicentre 
randomized controlled trial in patients with advanced HF 
(NYHA III-IV, LVEF≤35%, narrow QRS) who were 
treated with optimal medical therapy (213 patients) 
versus optimal medical therapy plus CCM device (215 
patients). Although no difference in the mean change of 
anaerobic threshold was found among the two groups, the 
trial revealed improved quality of life, peak VO2 and 
NYHA class in patients receiving CCM therapy.32 Further 
studies are needed to clarify how patients with end-stage 
HF should be treated in terms of when and which device 
should be implanted.   
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